Roger Dansey, Seagen interim CEO
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
After rumors of stalled buyout talks between Merck and Seagen, perhaps a new Tukysa indication could reignite interest.
The FDA has granted Tukysa a priority …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
